Bloomberg reported that Jay Bradner, head of Novartis R&D, revealed that after conducting a comprehensive pipeline asset assessment, Novartis has reduced its number of new drug projects from 430 to 340. Jay Bradner Bradner said: “We have a good understanding of the scientific foundation behind these 90 projects. Although… Continue Reading Novartis R&D begins to slim down, 90 new drug projects will be shelved or transferred
The birth of Gleevec is legendary and very touching. To understand the birth of a drug, we must first understand the disease that this drug treats. Gleevec is a medicine for the treatment of chronic myeloid leukemia, but not many people understand it in the early stages. We all know… Continue Reading The silver bullet that shot the Werewolf: the wonderful story behind the birth of Gleevec
EvaluatePharma’s report “World Preview 2018, Outlook to 2024” pointed out that Abbott Biotech drug Adalimumab will still defend the world’s best-selling drug list winner in 2024. Novartis will surpass Pfizer and Roche in 2024 to become the world’s largest prescription drug company with US$53.2 billion in revenue. In the increasingly… Continue Reading In 2024, the best-selling pharmaceutical company TOP10
Nature Medicine conducted two CRISPR related articles on Monday. Both studies found that the CRISPR-Cas9 system can induce intracellular p53-mediated DNA damage and affect CRISPR genome editing. CRISPR-related companies’ share prices dropped sharply after the article went live, CRISPR Therapeutics fell nearly 13%, Editas Medicine fell nearly 8%, Intellia Therapeutics… Continue Reading Nature issued a document, the stock price dropped! How does p53 affect the future of CRISPR?
Evaluate Pharma’s report “World Preview 2018, Outlook to 2024” published in BIO2018 recently pointed out that Novartis will surpass Pfizer and Roche in 2024 and become the world’s largest prescription drug company with a revenue of 53.2 billion U.S. dollars. Global Prescription Drug Corporation TOP10 in 2024 Analysts pointed… Continue Reading In 2024, Novartis will become the world’s largest pharmaceutical company?
In generic rivers and lakes, if Teva is compared to the Dragon Sword of the world, then the Heavenly Sword is none other than Sandoz. Although there is no big brother Teva crowned with that dazzling light, the imitation sharp edge in the hands is equally sharp; “My dad is… Continue Reading Global generic drugs giant inventory (2) | Sandoz: the soaring Germanic Eagle
IDO Inhibitor Stops Recruiting Patients in Multiple Clinical Trials On May 2, Incyte announced that multiple late-stage clinical trials of epacadostat with MSD, Bristol-Myers Squibb, and Aslicon PD-1/PD-L1 drugs will stop the recruitment of patients. At the same time, Bristol-Myers Squibb also stopped several clinical trials with the PD-1 combination… Continue Reading A week of news
This aspirin tablet-sized implant made from biodegradable materials will likely activate the patient’s anti-tumor immune response, thereby producing an anti-tumor effect. Implantable tumor vaccine Immunotherapy, which can activate the patient’s own immune system and kill tumor cells, is probably the hottest area of research and development of new drugs today.… Continue Reading Frontiers: Can tumor immune implants become a new breakthrough in cancer vaccines?